Drug management

Drug pricing & markets, value-based pricing, cost control, real-world evidence for safety and effectiveness

Cover Story
Lola Butcher
Insurers and pharmaceutical companies want ICER to umpire debates about drug prices. But some question the cost-effectiveness calculations of the Boston not-for-profit and its dependence on QALYs.
The Payers’ Playbook
Joseph Burns
A newspaper series and a state audit put a spotlight on PBM practices in Ohio. Congress and other states are also looking more closely at what PBMs are delivering to Medicaid health plans.
Viewpoint
Dea Belazi
PBMs can play an important role in the pharmaceutical supply chain and are positioned to protect consumers and save them out-of-pocket costs. The emergence of new PBMs, whether inside or outside an insurer, should drive new solutions and the development of new models.
Peter Wehrwein
A study designed to test whether eliminating copays would improve adherence to antiplatelet therapy showed that, yes, indeed, it does. But the results also showed no reduction in major cardiovascular events among those who stuck with the medication.
The contract between UPMC Health Plan and AstraZeneca will help the brand-name antiplatelet drug compete against generic versions of Plavix by lowering the copay to $10.
Ed Silverman
An Express Scripts analysis backs up industry claims that high-priced HIV medications may save money in the long run because they improve adherence.
The Value Proposition: PBM Mergers
Robert Calandra

Recent mergers didn’t quiet the growing frustration and concern employers, pharmacists, consumer advocates, state legislators, and some members of Congress have with the PBMs’ lack of transparency. There are still so many questions, and getting answers anytime soon will be a chore.

Q&A
Jennifer Graff
A conversation with Jennifer Graff, National Pharmaceutical Council VP